LIXT
NASDAQ HealthcareLixte Biotechnology Holdings, Inc. - Common Stock
Biotechnology
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
๐ Market Data
| Price | $7.04 |
|---|---|
| Volume | 303,867 |
| Market Cap | 87.18M |
| Beta | 1.050 |
| RSI (14-Day) | 70.7 Overbought |
| 200-Day MA | $4.01 |
| 50-Day MA | $4.14 |
| 52-Week High | $7.50 |
| 52-Week Low | $0.64 |
| Price / Book | 7.80 |
๐ฏ Investment Strategy Scores
LIXT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (86/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find LIXT in your text
Paste any article, transcript, or post โ the tool will extract LIXT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.